rr rs Corrected by th STIC Systems Branch Serial Numb r: Edited by: Verified by: (STIC staff) Changed a file from non-ASCII to ASCII Changed the margins in cases where the sequence text was "wrapped" down to the next line. Edited a format error in the Current Application Data section, specifically... Edited the Current Application Data section with the actual current number. The number inputted by the applicant was the prior application data; or ther _____. Added the mandatory heading and subheadings for "Current Application Data". Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer. Changed the spelling of a mandatory field (the headings or subheadings), specifically: Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were: Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited: Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place. Inserted colons after headings/subheadings. Headings edited included: Deleted extra, invalid, headings used by an applicant, specifically: Deleted: non-ASCII "garbage" at the beginning/end of files; secretary initials/filename at end of file; page numbers throughout text; other invalid text, such as_ Inserted mandatory headings, specifically: ___ Corrected an obvious error in the response, specifically: Edited identifiers where upper case is used but lower case is required, or vice versa. Corrected an error in the Number of Sequences field, specifically: A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted. Deleted ending stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a Patentin bug). Sequences corrected: _____ Other:

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.

3/1/95



OIPE

RAW SEQUENCE LISTING DATE: 03/12/2002 3/462
PATENT APPLICATION: US/10/079,075 TIME: 17:03:18

```
1 <110> APPLICANT: Ronald C. Montelaro
         Timothy A. Mietzner
 3 <120> TITLE OF INVENTION: VIRUS DERIVED ANTIMICROBIAL PEPTIDES
 4 <130> FILE REFERENCE: A34001-A / 072396.0222
 5 <140> CURRENT APPLICATION NUMBER: US/10/079,075
 6 <141> CURRENT FILING DATE: 2002-02-19
 7 <160> NUMBER OF SEQ ID NOS: 12
 8 <170> SOFTWARE: FastSEQ for Windows Version 3.0
10 <210> SEQ ID NO: 1
11 <211> LENGTH: 28
12 <212> TYPE: PRT
13 <213> ORGANISM: Artificial Sequence
14 <220> FEATURE:
15 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
16 <400> SEQUENCE: 1
17
         Arg Val Ile Arg Val Val Gln Arg Ala Cys Arg Ala Ile Arg His Ile
18
                           5
19
          Val Arg Arg Ile Arg Gln Gly Leu Arg Arg Ile Leu
22 <210> SEQ ID NO: 2
23 <211> LENGTH: 31
24 <212> TYPE: PRT
25 <213> ORGANISM: Artificial Sequence
26 <220> FEATURE:
27 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
28 <400> SEQUENCE: 2
          Arg Val Ile Arg Val Val Gln Arg Ala Cys Arg Ala Ile Arg His Ile
30
                                              10
31
          Val Arg Arg Ile Arg Gln Gly Leu Arg Arg Ile Leu Arg Val Val
                      20
34 <210> SEQ ID NO: 3
35 <211> LENGTH: 31
36 <212> TYPE: PRT
37 <213> ORGANISM: Artificial Sequence
38 <220> FEATURE:
39 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
40 <400> SEQUENCE: 3
          Arg Trp Ile Arg Val Val Gln Arg Trp Cys Arg Ala Ile Arg His Ile
41
42
43
          Trp Arg Arg Ile Arg Gln Gly Leu Arg Arg Trp Leu Arg Val Val
                      20
46 <210> SEQ ID NO: 4
47 <211> LENGTH: 12
```

RAW SEQUENCE LISTINGPATENT APPLICATION: US/10/079,075

DATE: 03/12/2002

TIME: 17:03:18

```
48. <212> TYPE: PRT
49 <213> ORGANISM: Artificial Sequence
50 <220> FEATURE:
51 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
52 <400> SEQUENCE: 4
          Arg Val Val Arg Val Val Arg Arg Val Val Arg Arg
53
54
           1
56 <210> SEQ ID NO: 5
57 <211> LENGTH: 24
58 <212> TYPE: PRT
59 <213> ORGANISM: Artificial Sequence
60 <220> FEATURE:
61 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
62 <400> SEQUENCE: 5
          Arg Arg Val Val Arg Arg Val Arg Val Arg Arg Val Val Arg
6.3
          Val Val Arg Arg Val Val Arg Arg
65
66
68 <210> SEO ID NO: 6
69 <211> LENGTH: 36
70 <212> TYPE: PRT
71 <213> ORGANISM: Artificial Sequence
72 <220> FEATURE:
73 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
74 <400> SEQUENCE: 6
          Val Arq Arq Val Val Arq Arq Val Val Arg Val Val Arg Arg Val Val
75
76
          Arg Arg Val Arg Arg Val Val Arg Val Val Arg Val Val Arg Arg
77
78
                                          25
79
          Val Val Arg Arg
82 <210> SEQ ID NO: 7
83 <211> LENGTH: 42
84 <212> TYPE: PRT
85 <213> ORGANISM: Artificial Sequence
86 <220> FEATURE:
87 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
88 <400> SEQUENCE: 7
          Arg Arg Val Val Arg Arg Val Arg Arg Val Val Arg Arg Val Val Arg
89
90
         Val Val Arg Arg Val Val Arg Arg Val Arg Arg Val Arg Arg Val
92
                                          25
93
          Val Arg Val Val Arg Arg Val Val Arg Arg
96 <210> SEQ ID NO: 8
97 <211> LENGTH: 48
98 <212> TYPE: PRT
99 <213> ORGANISM: Artificial Sequence
100 <220> FEATURE:
```

RAW SEQUENCE LISTING DATE: 03/12/2002 PATENT APPLICATION: US/10/079,075 TIME: 17:03:18

```
101 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
102 <400> SEOUENCE: 8
           Arg Val Val Arg Val Val Arg Arg Val Arg Arg Val Arg Arg Val
103
104
           1
        , Val Arg Arg Val Val Arg Val Val Arg Arg Val Arg Arg Val Arg
105
106
           Arg Val Val Arg Arg Val Val Arg Val Arg Arg Val Val Arg Arg
107
108
                                       40
110 <210> SEQ ID NO: 9
111 <211> LENGTH: 12
112 <212> TYPE: PRT
113 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
116 <400> SEQUENCE: 9
           Arg Val Val Arg Val Val Arg Arg Trp Val Arg Arg
                                               10
118
            1
                            5
120 <210> SEQ ID NO: 10
121 <211> LENGTH: 24
122 <212> TYPE: PRT
123 <213> ORGANISM: Artificial Sequence
124 <220> FEATURE:
125 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
126 <400> SEQUENCE: 10
           Arg Arg Trp Val Arg Arg Val Arg Arg Val Trp Arg Arg Val Val Arg
127
128
                                               10
129
           Val Val Arg Arg Trp Val Arg Arg
130
                       20
132 <210> SEQ ID NO: 11
133 <211> LENGTH: 36
134 <212> TYPE: PRT
135 <213> ORGANISM: Artificial Sequence
136 <220> FEATURE:
137 <223> OTHER INFORMATION: Artificial peptide derived from HIV-1
138 <400> SEQUENCE: 11
           Val Arg Arg Val Trp Arg Arg Val Val Arg Val Arg Arg Trp Val
139
140
           Arg Arg Val Arg Arg Val Trp Arg Arg Val Val Arg Val Val Arg Arg
141
142
                                           25
143
           Trp Val Arg Arg
144
                   35
146 <210> SEQ ID NO: 12
147 <211> LENGTH: 48
148 <212> TYPE: PRT
149 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:
151 <223> OTHER INFORMATION: artificial peptides derived from HIV-1
152 <400> SEQUENCE: 12
          Arg Val Val Arg Val Val Arg Arg Trp Val Arg Arg Val Arg Arg Val
153
```

RAW SEQUENCE LISTING DATE: 03/12/2002 PATENT APPLICATION: US/10/079,075 TIME: 17:03:18

154	1				5					10					15	
155	Trp	Arg	Arg	Val	Val	Arg	Val	Val	Arg	Arg	Trp	Val	Arg	Arg	Val	Arg
156				20					25					30		
157	Arg	Val	Trp	Arg	Arg	Val	Val	Arg	Val	Val	Arg	Arg	Trp	Arg	Val	Val
158			35					40					45			

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/079,075

DATE: 03/12/2002 TIME: 17:03:19